SURVYR

CRC

California Resources Corporation
$54.11
−$0.64 (1.17%)Oct 27 close
EnergyS&P 600 CompareTechnicals
Model valuationLooks undervaluedDCF base $104
1M3M6M1Y2Y
-7%+9%+25%+41%+57%Oct 2025Oct 2026Apr 202652w high $71.9852w low $43.24
CRCSPY
Wall St. Highest PT $91.00 (+68.2%) Wall St. Avg PT $75.33 (+39.2%)
$43$58$74$90$106POC $53Hi $91Avg $75
Underwater Drawdown %Max DD -29.2%Current -21.7%
0.0%-29.2%
Relative Strength vs SPY+4.2% vs SPYOutperforming
+63%0%-63%
1W
−$0.16 (0.29%)
1M
+$1.60 (3.05%)
3M
+$5.18 (10.60%)
6M
−$11.56 (17.60%)
YTD
+$10.32 (23.57%)
1Y
+$8.14 (17.70%)

Chart

Loading live chart…

Ratings & dials

1m · 5m · 15m · 1h · 4h · 1D

Analyst & Morningstar ratings

Consensus · Targets · Morningstar
Wall Street analyst consensus
SellHoldStrong Buy
Strong Buy
13 analysts · mean score 1.38
1 = Strong Buy · 5 = Sell
Strong Buy323%
Buy969%
Hold18%
Underperform00%
Sell00%
Wall Street consensus
Analyst price targets
Current price$54.11
Average target$75.33
+$21.22 (+39.2%) upsideaverage target vs current price
CurrentAverageMedian
Low$59.00
Median$75.00
High$91.00
12-month Wall Street target range
Recent analyst rating changes · 30
Reiterated
2026-10-12 · UBS reiterated Buy on CRC
Reiterated
2026-09-18 · Stephens & Co. reiterated Overweight on CRC
Reiterated
2026-09-17 · Roth Capital reiterated Buy on CRC
Reiterated
2026-09-14 · UBS reiterated Buy on CRC
Reiterated
2026-09-14 · RBC Capital reiterated Outperform on CRC
Initiated
2026-09-03 · Seaport Global started covering CRC at Neutral
All analyst rating changes ›

Third-party ratings, not SURVYR.'s views.

Health check

Quality
WeakAverageStrong
Average
Piotroski F-score 4 of 9
See the tests
  • ✓Positive net income
  • ✓Positive operating cash flow
  • ✗Return on assets improved
  • ✓Cash flow above net income
  • ✗Long-term debt / assets fell
  • ✗Current ratio improved
  • ✗No share dilution
  • ✗Gross margin improved
  • ✓Asset turnover improved

Computed by SURVYR. from the company's SEC filings (latest balance sheet Jun 30, 2026). Descriptive, not a forecast.

Key stats & company

Market value$4.8B
P/E (next 12 months, estimated)15.6
52-week range$43.24 – $71.98
Revenue growth (latest quarter vs a year ago)+33.0%
Dividend yield2.97%
Analyst consensusStrong Buy (12)
Average analyst price target$75.33 (+39%)

What they do

California Resources Corporation operates as an independent energy and carbon management company in the United States. The company operates in two segments, Oil and Natural Gas, and Carbon Management. It explores, develops, and produces crude oil, oil condensate, natural gas liquids and natural gas to california refineries, marketers, and other purchasers.

Energy · Oil & Gas E&P
Valuation and fundamentals

Valuation & fundamentals

Bottom line
Looks undervalued
Model read-out from the numbers below, not advice. Score +3 (DCF counts double).
▲DCF (base case)above the price by 92%
•Forward P/E vs sector15.6x vs median 13.6x
•Piotroski F-score4/9
•Net debt / EBITDA2.9x
▲Analyst target+39% (12 analysts)

Discounted cash flow

CyclicalValued on average-cycle margins
Bear
$46
-15%
growth 13% · disc. 10.3% · term. 2.0%
Base
$104
+92%
growth 22% · disc. 9.3% · term. 2.5%
Bull
$190
+250%
growth 27% · disc. 8.3% · term. 3.0%

Starting cash flow is mid-cycle: 7.7% average margin × current revenue = 0.2B (last 12 months: 0.4B at a 12% margin). On trailing cash flow the base case would be $170.

Reverse DCFfor context, not a signal
Today's price assumes free cash flow grows about 9% a year for 10 years.
Implied
+9%/yr
FCF, last 3 yrs
+20%/yr
FCF, last 5 yrs
+20%/yr
Revenue, last 3 yrs
+11%/yr
Revenue, last 5 yrs
+7%/yr
Same inputs as the DCF above: mid-cycle free cash flow 0.2B, 9.3% discount rate, 2.5% growth after year 10, net debt and today's share count. Actual growth rates are compound annual rates from SEC annual filings through FY2025; "n/a" means too little history or a negative starting year.
Edit assumptions · recalculates instantly
Your value per share–

Free cash flow = operating cash flow − capital spending, trailing 12 months (TTM to 2026-06-30). Growth default: average of 3-year revenue CAGR and latest revenue growth, capped at 30%. Years 6–10 fade linearly to terminal growth. Discount rate = 4.25% risk-free assumption + beta 1.02 × 5% equity premium, kept within 7–13%. Bear: lower growth, +1 pt discount, 2% terminal. Bull: higher growth, −1 pt, 3%.

Multiples vs Energy

P/E (trailing)
sector median 18.1×
 –
Forward P/E
sector median 13.6× · 67th pct
 15.6×
pricier
EV / EBITDA
sector median 8.1× · 83rd pct
 13.4×
pricier
Price / sales
sector median 2.3× · 29th pct
 1.5×
cheaper
Price / book
sector median 1.9× · 26th pct
 1.4×
cheaper
FCF yield
sector median 7.6% · 52nd pct
 7.9%
cheaper

Forward EPS $3.50 vs trailing $-1.29. Forward P/E uses analysts' next-12-month estimate.

Quality & financial health

Gross margin
31.0%
Operating margin
-1.7%
FCF margin
12.1%
Net margin
-3.8%
Return on equity
-3.6%
Return on invested capital
-0.9%
Net debt / EBITDA
2.9×
Current ratio
0.7×
Interest cover
–
Cash conversion (OCF/NI)
–
Piotroski F-score 4/9 · last two fiscal years
✓ Positive net income✓ Positive operating cash flow✗ Return on assets improved✓ Cash flow above net income✗ Long-term debt / assets fell✗ Current ratio improved✗ No share dilution✗ Gross margin improved✓ Asset turnover improved

Analysts

Mean target
$75
+39%
Analysts
12
Strong Buy
Range
$59–$91
low – high
● price · ◆ mean target

Annual history

FYRevenueNet incomeFree cash flow
2025$3.7B$363.0M$543.0M
2024$3.2B$376.0M$355.0M
2023$2.8B$564.0M$468.0M
2022$2.7B$524.0M$311.0M
2021$1.9B$612.0M$466.0M
2019$2.6B$-28.0M$221.0M

From the company's 10-K filings via SEC XBRL. 3-year revenue CAGR +10.7%.

For information only · Important disclosures

Grades vs sector

Momentum
24th percentile in sector
D+
12-1 return: +10.9%
Percentile within its GICS sector across the S&P 1500.
Growth
59th percentile in sector
B-
Revenue growth (YoY): +33.0%
Percentile within its GICS sector across the S&P 1500.
Value
31st percentile in sector
D+
Forward E/P: 6.6% · EBITDA/EV: 8.9%
Percentile within its GICS sector across the S&P 1500.
Profitability
9th percentile in sector
D-
Profit margin: -3.2% · Return on equity: -3.6%
Percentile within its GICS sector across the S&P 1500.
Revisions
Not enough data yet
–
EPS estimate change, 30 days (current FY): –
30-day change in analysts' current-year EPS estimate; graded across covered stocks.

Systematic Models

Not held by any of our 7 live models right now.

Quality Growth
Outside this model's universe or screens
 Momentum Top 15
Outside this model's universe or screens
 Momentum Blend
Not in the current book
 New Highs Growth
Outside this model's universe or screens
 SURVYR. Barbell Momentum & T-Bill Shield
Outside this model's universe or screens
 SURVYR. Physical AI Grid & Power
Outside this model's universe or screens
 SURVYR. Long Book
Not in the current book

Earnings & events

CRC earningsNext report in 5 days
Next report · quarter Sep 2026
Mon Nov 2, 2026After the close
EPS consensus$0.97 range $0.76–$1.12
Revenue consensus$946.7M 6 analysts
Last 4 quarters · EPS vs estimate
Aug 10, 2026$0.99est $1.37−28.0%Below estimates
May 5, 2026$0.88est $0.90−2.2%Below estimates
Mar 2, 2026$0.47est $0.50−6.3%Below estimates
Nov 4, 2025$1.46est $1.27+14.6%Above estimates

In line = within 1% of the estimate.

Source: Yahoo Finance · report time: Nasdaq earnings calendar · refreshed 2026-10-25 16:44:50 ET
24-1125-0325-0525-0825-1126-0326-0526-080.001.50
EstimateActual (beat)Actual (miss)

Quarterly revenue

QuarterRevenueYoY
2026-06-30$1.1B+33.0%
2026-03-31$967.0M–
2025-12-31$798.0M–
2025-09-30$878.0M–
2025-06-30$821.0M–

Recent dividends

2026-09-04: $0.405 · 2026-05-29: $0.405 · 2026-03-13: $0.405 · 2025-12-01: $0.405 · 2025-08-27: $0.388 · 2025-05-30: $0.388 · 2025-03-10: $0.388 · 2024-12-02: $0.388

News & catalysts

More news
Quanta Presents Positive Clinical Combination Data in KRAS G12D-Mutant CRC at ESMO and Highlights Pan-KRAS Progress
GlobeNewswire · Oct 24
Freenome Expands Personalized Cancer Detection Portfolio, Launching SimpleScreen™ Lung Test With FDA-Approved SimpleScreen CRC Option
GlobeNewswire · Oct 20
Riboscience to Present First Overall Survival and Immune Activation Data from Phase 1b Study of ENPP1 Inhibitor RBS2418 as Monotherapy and in Combination in Advanced Metastatic Cancers Including MSS CRC, at ESMO 2026
PR Newswire · Oct 19
Quanta Therapeutics Announces Presentation of QTX3034 Clinical Combination Data with Anti-EGFR and Chemotherapy in Colorectal Cancer (CRC) at ESMO and Fast Track Designation for Patients with KRAS G12D Mutations
GlobeNewswire · Oct 19
3 U.S. Energy Stocks Investors Are Watching As Oil And Gas Prices Stay High
Simply Wall St. · Oct 17
Rating changes
Reiterated
2026-10-12 · UBS reiterated Buy on CRC
Reiterated
2026-09-18 · Stephens & Co. reiterated Overweight on CRC
Reiterated
2026-09-17 · Roth Capital reiterated Buy on CRC
Reiterated
2026-09-14 · UBS reiterated Buy on CRC
Reiterated
2026-09-14 · RBC Capital reiterated Outperform on CRC
Initiated
2026-09-03 · Seaport Global started covering CRC at Neutral

Third-party analyst actions, not SURVYR.'s views. All rating changes

Insider trades
Bys Jay A.
EVP & Chief Commercial Officer · 2026-10-12
Sell
$643.0K
Bys Jay A.
EVP & Chief Commercial Officer · 2026-09-04
Sell
$643.0K
Bys Jay A.
EVP & Chief Commercial Officer · 2026-08-10
Sell
$643.0K

Stats refreshed 2026-10-25 16:44:50 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now

Morning Brief (8 AM ET) & Market Close (4:30 PM ET), weekdays

Indexes, sectors, biggest movers, rates, top news, SURVYR. model changes and what's ahead. Free, two short emails each weekday.

Editions

Free. Not investment advice. Unsubscribe anytime.

SURVYR

Free to use. No card, no ads, no auto-renew.

Systematic research · Not investment advice · Hypothetical unless marked Live · Data: Yahoo Finance (15-min delayed), SEC EDGAR, House Clerk · Important disclosures · Contact desk@coteau.app

How it worksOur promiseTermsPrivacyData statusSend feedback
Coteau 0.9 · Oct 21, 2026